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Abstract 
Background: Current guidelines recommend newer generation drug-eluting stents (DES) 
over bare-metal stents (BMS) in patients with ischemic heart disease. However, there is no 
age-specific recommendation in elderly patients. 
Methods:  Meta-analysis was performed of 6 randomized studies enrolling 5,042 elderly 
patients who underwent percutaneous coronary intervention (PCI) with stent implantation 
(DES, n = 2,579; BMS, n = 2,463). 
Results: Combined data indicated a significant reduction in major adverse cardiovascular 
events (MACEs) with use of DES (odds ratio [OR] 0.56, 95% confidence interval [CI] 0.44–
0.71, p < 0.001). Moreover, use of DES was associated with a significantly lower incidence 
of myocardial infarction (OR 0.54, 95% CI 0.36–0.81, p = 0.003) and repeat 
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revascularization (OR 0.44, 95% CI 0.31–0.62, p < 0.001), was compared to that with the use 
of BMS. Stent thrombosis and bleeding complication rates were not significantly different 
between groups. In a subgroup meta-analysis, short duration (1 or 6 months) dual antiplatelet 
therapy (DAPT) was associated with a significantly lower MACE rate (OR 0.49, 95% CI 
0.34–0.80; p = 0.003) in elderly patients who underwent PCI with everolimus-eluting stent 
(EES) implantation, compared with that using long duration DAPT. 
Conclusions: This meta-analysis provides clinically relevant evidence that DES rather than 
BMS should be selected for elderly patients. 
Key words: drug-eluting stent, bare-metal stent, elderly, clinical trials, clinical research 
 
 
Introduction 
The introduction of drug-eluting stents (DES) and advanced pharmacotherapy 
resulted in a significant reduction in restenosis rates [1–5]. This improvement, however, 
increased the prevalence of bleeding complications due to use of DES and longer duration of 
dual antiplatelet therapy (DAPT), compared to that using bare-metal stents (BMS) [6]. Long 
duration of DAPT after DES deployment was associated with higher risk of major bleeding 
complications despite the beneficial effects of novel platforms, especially in vulnerable 
populations such as patients over 75 years old [7]. 
Until recently, guidelines have not provided evidence-based recommendations for 
treatment of elderly patients [8]. Recently, the SYNERGY II Everolimus eluting stent in 
patients older than 75 years, undergoing coronary revascularization associated with a short 
dual antiplatelet therapy (SENIOR) trial demonstrated that use of DES rather than BMS in 
patients older than 75 years results in lower adverse clinical event rates at 1 year [9]. These 
observations were also previously seen in the Xience or Vision Stents for the Management of 
Angina in the Elderly (XIMA) trial, which demonstrated a reduction in myocardial infarction 
(MI) and in-stent restenosis in the DES group without an increase in bleeding [10]. The 
superiority of DES in the SENIOR trial was mainly due to a reduction of target lesion 
revascularization (TLR), but there were no significant differences between all-cause death, 
MI, and stroke. Therefore, it is unclear whether the clinical benefits of DES were 
overestimated [11]. Herein, a meta-analysis was performed of randomized studies aiming to 
assess the benefits and risks associated with DES versus BMS use for percutaneous coronary 
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intervention (PCI) in elderly patients. 
 
Methods 
This study was designed in accordance with the Preferred Reporting Items for Systematic 
reviews and Meta-Analyses (PRISMA) guidelines [12]. A comprehensive MEDLINE, 
EMBASE, and Cochrane database search was conducted until September 6, 2018, using the 
following medical subject headings alone and in different combinations: “drug-eluting 
stent(s)”, “DES”, “bare-metal stent(s)”, “BMS”, “coronary artery disease” and “elderly 
patients”. Randomized studies that evaluated elderly patients undergoing PCI and reported on 
clinical outcomes with follow-up time ≥ 12 months were included. Conventionally, “elderly” 
has been defined as a chronological age of ≥ 65 years. In the present study however, elderly 
patients were defined as > 70 years old. Only full articles in peer-reviewed journals were 
considered. 
Two investigators (SAB, YK) extracted baseline study characteristics, clinical outcomes, 
and DAPT duration of interest from the retrieved studies. Any divergences were resolved by 
consensus. The number of events associated with clinical outcomes was tabulated for the 
longest follow-up available. 
The primary endpoint was major adverse cardiovascular events (MACEs), defined as a 
composite of cardiac death, MI, and repeat revascularization, including TLR and target vessel 
revascularization (TVR). Secondary endpoints were individual components of MACE, 
definite/probable stent thrombosis, as defined by the Academic Research Consortium, and 
bleeding complications according to both Thrombolysis in Myocardial Infarction and 
Bleeding Academic Research Consortium classifications [13, 14]. Subgroup meta-analysis of 
DES implantation with short (1 or 6 months) versus long (> 12 months) DAPT duration was 
performed to determine MACE, stent thrombosis, and bleeding complication rates. Moreover, 
a meta-regression analysis was performed to identify moderators in a linear relationship 
among baseline characteristics according to the percentage of hypertension, diabetes mellitus, 
dyslipidemia, and acute coronary syndrome (ACS). The SENIOR trial was included in the 
short DAPT group, while the XIMA, Basel Stent Kosten Effektivitäts Trial-PROspective 
Validation Examination (BASKET-PROVE), and Everolimus-Eluting Stents Versus Bare-
Metal Stents in ST-Segment Elevation Myocardial Infarction (EXAMINATION) trials were 
included in the long DAPT group. 
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Quality assessment was performed for both study groups.  The risk of bias was assessed 
of each study with the Cochrane tool and the Grading of Recommendations, Assessment, 
Development and Evaluation (GRADE) tool [15, 16] was used to assess quality as high, 
moderate, low, or very low. Most clinical trials showed low evidence of bias with the 
Cochrane tool. In addition, the level of evidence was strong for primary outcomes assessed 
with the GRADE tool.  
 
Statistical analysis 
The number of patients, events, means, standard deviations (SDs), and percentages were 
abstracted. Estimates were calculated with a random effects model and confirmed with a 
fixed effects model and was expressed as odds ratios (ORs). A p-value ≤ 0.05 (2-tailed) 
indicated statistical significance.  The random effects model was prioritized over the fixed 
effects model and sensitivity analysis was conducted to identify sources of inconsistency. The 
I2 statistic was used for evaluation of heterogeneity between studies with values of < 30%, 30% 
to 60%, and > 60%, corresponding to low, moderate, and high degrees of heterogeneity, 
respectively [17]. Publication bias was assessed using both the Egger and Begg’s tests. A p-
value < 0.05 indicated evidence of bias [18]. All data analyses were performed using R 
version 3.5.0 (R Foundation for Statistical Computing, Vienna, Austria). This study was 
registered with PROSPERO, number CRD42019112969. 
 
Results 
The flow chart of the study selection process is shown in Figure 1. Six multi-center 
randomized controlled trials enrolling 5,042 elderly patients with coronary artery disease 
(CAD), who underwent PCI with either DES (n = 2,579) or BMS (n = 2,463) implantation 
were included [9, 10, 19–22]. The study design and characteristics of the trials involved are 
shown in Table 1. When studies reported results from both unmatched and matched 
populations, data regarding the matched subgroup were considered. The mean follow-up 
completion for all trials was relevant, with an overall rate of 98%. The recommended DAPT 
duration varied between trials (1–12 months), but was the same in both the DES and BMS 
groups, except in the XIMA trial (1 month of DAPT for patients receiving BMS and 12 
months for patients receiving DES). 
During long-term follow-up (range 1–2 years), combined data indicated a significant 
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reduction in MACE with DES use (OR 0.56, 95% confidence interval [CI] 0.44–0.71, p < 
0.001, Fig. 2A). There was no significant difference in stent thrombosis between groups (OR 
0.68, 95% CI 0.40–1.14, p = 0.142, Fig. 2B). Bleeding complication rates were similar for 
both groups (OR 0.96, 95% CI 0.78–1.18, p = 0.686, Fig. 2C). In addition, the risk of cardiac 
death did not differ between the groups (OR 0.81, 95% CI 0.65–1.02, p = 0.075, Fig. 3A). 
However, use of DES rather than BMS was associated with a significantly lower incidence of 
MI (OR 0.54, 95% CI 0.36–0.81, p = 0.003, Fig. 3B) and repeat revascularization (OR 0.44, 
95% CI 0.31–0.62, p < 0.001, Fig. 3C). The funnel plots and the Egger and Begg tests did not 
suggest any significant publication bias (Fig. 4).  
In elderly patients who underwent PCI with everolimus-eluting stent (EES) implantation, 
subgroup meta-analysis showed a significant decrease in MACE in the short DAPT (1 or 6 
months) group (OR 0.49, 95% CI 0.34–0.80; p = 0.003), without statistical heterogeneity (I2 
= 23.7%; p = 0.08; Fig. 5A). However, there were no significant differences in stent 
thrombosis and bleeding complication rates according to DAPT duration (Fig. 5B, C). 
Subgroup analysis showed a significant decrease in MACE with all DES types, including 
EESs, biolimus-eluting stents, and zotarolimus-eluting stents (ZESs). Moreover, use of a ZES 
was associated with a significantly lower incidence of definite/probable stent thrombosis (OR 
0.40, 95% CI 0.20–0.83; Fig. 6). 
 
Discussion 
The main findings of the present study were as follows: 1) DES deployment was associated 
with significant reduction in MACE, MI, and repeat revascularization in elderly patients; 2) 
DES implantation was associated with the risk of stent thrombosis and bleeding 
complications similar to that of BMS implantation; 3) In subgroup meta-analysis, clinical 
outcomes were similar for short and long DAPT duration in elderly patients who underwent 
PCI with EES implantation. 
Current guidelines recommend stenting with the newer generation of DES rather than BMS 
in patients with ischemic heart disease including ST-segment elevation myocardial infarction 
(STEMI), because of better efficacy and safety profiles [23, 24]. Moreover, guidelines 
support DES as the preferred treatment option regardless of DAPT duration in patients with 
high bleeding risk [25]. Nevertheless, age-specific recommendations in elderly patients are 
not available; thus, BMS has been the preferred option in elderly patients due to shorter 
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DAPT duration [8]. 
As shown in Table 2, the results of  6 randomized trials , including 4 studies involving 
patients older than 80 years of age on average, can be seen as appropriate evidence to 
determine PCI strategy in elderly patients. However, differences in the definitions of primary 
and secondary outcomes make it difficult to comprehensively assess the benefits of DES in 
the treatment of elderly patients. The beneficial effects of DES on all-cause death have only 
been reported in a sub-study of the BASKET-PROVE trial [21]. Furthermore, the cardiac 
death rate was comparable to that in  6 of the studies included. In contrast to the other 4 
randomized studies, the SENIOR trial and sub-study of the EXAMINATION trial did not 
show a difference in the risk of MI in both the DES and BMS groups [9, 22]. Particularly in 
the sub-study of the EXAMINATION trial for STEMI patients, DES use did not show any 
benefits over BMS use in patients over 75 years old [22]. In meta-analysis, DES use was 
associated with a significant reduction in redefined MACE, including cardiac death, MI, and 
repeat revascularization. Except for the sub-study of the EXAMINATION trial, the studies 
included showed benefits of DES use for MACE in elderly patients. Furthermore, our pooled 
analysis demonstrated that PCI with DES implantation was apparently superior to BMS use 
in terms of MI and repeat revascularization. The Norwegian Coronary Stent Trial 
(NORSTENT), a large randomized trial comparing long-term outcomes after DES (n = 4,504) 
versus BMS use (n = 4,509), reported results similar to those inthe present study, with a 
significantly lower rate of repeat revascularization at 6 years in the group receiving DES [26]. 
However, NORSTENT enrolled relatively younger patients, and did not show the benefits of 
DES use for MI compared with the findings in the present study. Although it is difficult to 
compare the outcomes of MI between the NORSTENT and the present study, the differences 
may reflect the significant benefit of DES for elderly patients who tend to have more 
extensive and complex lesions. The risk of stent thrombosis and bleeding complications with 
use of DES was comparable to that of BMS in the 6 trials included and the NORSTENT. This 
tendency was also observed in the meta-analysis. Therefore, when considering efficacy and 
safety, DES use should be considered in elderly patients, as described in the current 
guidelines. 
The scoring systems used to determine DAPT duration include the DAPT score and 
PREdicting bleeding Complications in patients undergoing Stent implantation and subsequent 
Dual Anti Platelet Therapy (PRECISE-DAPT) [27, 28]. In both scoring models, age has been 
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used to assess bleeding and ischemic risk since post-PCI bleeding complications were 
associated with a significant increase in adverse clinical outcomes in patients older than 75 
years of age [29]. However, the usefulness of these scores for improving outcomes remains 
unclear, due to the lack of evidence in the setting of randomized controlled trials. According 
to current guidelines, short DAPT duration should be considered in patients with high 
bleeding risk (PRECISE-DAPT score ≥ 25), with 3 months of DAPT for stable CAD and 6 
months of DAPT for ACS [25]. The current subgroup meta-analysis in elderly patients who 
underwent PCI with EES implantation showed no significant differences between use of short 
DAPT duration and long DAPT duration in stent thrombosis and bleeding complications, as 
shown in Figure 5. Moreover, short DAPT duration was associated with a significantly lower 
incidence of MACE, compared with using long DAPT duration. Therefore, short DAPT 
duration is as safe as long DAPT duration in elderly patients who undergo PCI with EES 
implantation. 
 
Limitations of the study 
There were several limitations in this study. First, there was considerable heterogeneity 
between studies, which was particularly evident when comparing studies using different 
designs. Second, the definition of MACE was different in each study. Therefore, MACE was 
redefined to reduce confounders. Third, the definition of elderly varies from 65 to 75 years of 
age, but the present study defined elderly to be > 70 years of age, since there have been few 
randomized controlled trials in those aged ≥ 75 years. Fourth, differences in DAPT duration 
according to DES or BMS use were reported in only 1 of the 6 trials included (XIMA trial: 1 
month of DAPT for patients receiving BMS and 12 months for those receiving DES), which 
could affect outcomes. Fifth, there are two types of EES, durable polymer EES (XIENCETM, 
Abbott Vascular, Santa Clara, CA, USA) and bioabsorbable polymer EES (SYNERGYTM, 
Boston Scientific, Marlborough, MA, USA). Bioabsorbable polymer (BP)-DES implantation 
was reported to have better endothelial healing and conjugate protein expression than durable 
polymer-DES implantation [30]. Unique characteristics of BP-DES might affect the results of 
short and long DAPT duration on subgroup analysis. However, subgroup analysis included 
bioabsorbable or durable polymer EES. In addition, the proportion of ACS patients could not 
be assessed in the short and long DAPT duration groups and the comparison of DAPT 
duration was not randomly allocated between studies. Thus, a careful interpretation of 
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subgroup analysis of DAPT duration is necessary. 
 
Conclusions 
This meta-analysis builds upon recent evidence to support the efficacy and safety of DES 
use, and provides clinically relevant evidence that DES rather than BMS should be selected 
for treatment of elderly patients. Furthermore, short DAPT duration should be considered 
when PCI with EES implantation is performed in elderly patients. 
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Figure 1. Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) 
flow chart for the trial selection process. 
 
Figure 2. Forest plot for the risk of major adverse cardiovascular event (MACE; A), 
definite/probable stent thrombosis (B), and bleeding (C) in elderly patients treated with drug-
eluting stents (DES) versus bare-metal stents (BMS); df — degree of freedom. 
 
Figure 3. Forest plot for the risk of cardiac death (A), myocardial infarction (B), and repeat 
revascularization (C) in elderly patients treated with drug-eluting stents (DES) versus bare-
metal stents (BMS); df — degree of freedom. 
 
Figure 4. Funnel plot. 
 
Figure 5. Subgroup meta-analysis of the effect of short (≤ 1 or 6 months) versus long (> 12 
months) dual antiplatelet therapy (DAPT) duration in elderly patients who underwent 
percutaneous coronary intervention (PCI) with everolimus-eluting stent (EES) implantation.  
 
Figure 6. Subgroup meta-analysis of the effect according to drug-eluting stents (DES) type. 
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Table 1. Randomized controlled trials design characteristics of included studies. 
Study Year Design DES device 
Control 
device 
Follow-up 
(months) 
Total patients 
(DES/BMS) 
Follow-up 
completion 
Recommended 
duration of 
DAPT 
Primary outcome 
SENIOR trial [9] 2018 Multicenter 
randomized 
Everolimus 
(synergy II) 
BMS 
(Omega or 
Rebel) 
12 596/604 98% Stable: 1 month 
ACS: 6 months 
All death, MI, TLR, or stroke 
LEADERS FREE 
sub-study [19] 
2017 Multicenter 
randomized 
Biolimus 
(biofreedom) 
BMS 
(Gazelle) 
12 789/775 97% 1 month  
(all group) 
Cardiac death, MI, TLR, stent 
thrombosis, or bleeding (BARC 
3–5) 
ZEUS sub-study 
[20] 
2016 Multicenter 
randomized 
Zotarolimus 
(endeavor) 
BMS 
(Skylor, 
Vision, etc) 
12 424/404 100% 1 month 
(all group) 
All death, MI, or TVR 
BASKET-PROVE 
sub-study [21] 
2015 Multicenter 
randomized 
Everolimus 
(Xiencce) + 
Sirolimus 
(Cypher) 
BMS 
(Vision) 
24 258/147 96% 12 months 
(all group) 
Cardiac death or MI 
EXAMINATION 
sub-study [22] 
2015 Multicenter 
randomized 
Everolimus 
(Xience) 
BMS 
(Vision) 
12 113/132 97% 12 months 
(all group) 
All death, MI or repeat 
revascularization 
XIMA trial [10] 2014 Multicenter 
randomized 
Everolimus 
(Xience) 
BMS 
(Vision) 
12 399/401 100% BMS: 1 month 
DES: 12 months 
All death, MI, CVA, TVR, or 
bleeding (TIMI major) 
ACS — acute coronary syndrome; BARC — Bleeding Academic Research Consortium; BASKET-PROVE — Basel Stent Kosten Effektivitäts Trial–Prospective 
Validation Examination; BMS — bare metal stent; CVA — cerebrovascular accident; EXAMINATION — Everolimus-Eluting Stents vs Bare-Metal Stents in ST-Segment 
Elevation Myocardial Infarction; LEADERS FREE — prospective, double-blind, randomized comparison of the Biofreedom Biolimus A9 Drug-Coated Stent vs the 
Gazelle Bare-Metal Stent in patients at high bleeding risk; MI — myocardial infarction; SENIOR — drug-eluting stents in elderly patients with coronary artery disease; 
TIMI — Thrombolysis In Myocardial Infarction; TLR — target lesion revascularization; TVR — target-vessel revascularization; XIMA — Xience or Vision Stents for the 
Management of Angina in the Elderly; ZEUS — Zotarolimus-Eluting vs Bare Metal Stents in Uncertain Drug-Eluting Stent Candidates 
 
 
Table 2. Baseline characteristics of individuals enrolled in the clinical trials. 
Variable SENIOR trial [9] LEADERS FREE sub-study 
[19] 
ZEUS sub-study [20] BASKET-PROVE sub-study 
[21] 
EXAMINATION sub-study 
[22] 
XIMA trial [10] 
14 
 
 DES BMS DES BMS DES BMS DES BMS DES BMS DES BMS 
Numbers of patients 1,200 (596 vs 604) 1,564 (789 vs. 775) 828 (424 vs. 404) 405 (258 vs. 147) 245 (113 vs. 132) 800 (399 vs. 401) 
Age (years) 
81.4 ± 
4.3 
81.4 ± 
4.2 
81.3 ± 4.3 81.3 ± 4.3 80.4 80.5 79.1 ± 3.4 79.1 ± 3.6 ≥ 75 years 83.6 ± 3.2 83.4 ± 3.1 
Men 
368 
(62%) 
379 
(63%) 
504 (63.9%) 492 (63.5%) 
274 
(61.6%) 
259 
(64.1%) 
130 (50.4%) 93 (63.3%) 72 (63.7%) 87 (64.9%) 
245 
(61.1%) 
237 
(59.1%) 
Body mass index 
26.3 ± 
4.3 
25.9 ± 
3.9 
26.9 ± 4.3 26.5 ± 4.0 26 [24-29] 26 [24-29] – – 27.4 ± 3.77 27.6 ± 3.85 – – 
Diabetes mellitus 
158 
(27%) 
157 
(26%) 
248 (31.4%) 214 (27.6%) 
137 
(32.3%) 
117 (29%) 41 (15.9%) 21 (14.3%) 27 (23.6%) 33 (25%) 
103 
(25.6%) 
97 (24.2%) 
Hypertension 
427 
(72%) 
488 
(81%) 
615 (77.9%) 618 (79.8%) 
344 
(81.1%) 
336 
(83.2%) 
194 (75.2%) 102 (69.4%) 71 (62.8%) 94 (71.2%) 
301 
(75.1%) 
311 
(77.6%) 
Dyslipidemia 
311 
(52%) 
320 
(53%) 
474 (60.1%) 458 (59.1%) 191 (45%) 
193 
(47.8%) 
145 (56.2%) 84 (57.1%) 38 (33.6%) 43 (32.6%) 
231 
(57.6%) 
212 
(52.9%) 
Smoker 43 (7%) 38 (6%) – – 44 (10.4%) 45 (11.1%) 31 (12.2%) 21 (14.3%) – – 20 (5%) 16 (4%) 
Previous stroke 39 (7%) 48 (8%) 80 (10.1%) 66 (8.5%) 32 (7.5%) 34 (8.4%) 15 (5.8%) 11 (7.5%) 5 (4.4%) 7 (5.3%) 31 (7.8%) 43 (10.7%) 
Previous MI 
109 
(18%) 
80 (13%) 155 (19.7%) 154 (19.9%) 
117 
(27.6%) 
114 
(28.2%) 
45 (17.4%) 26 (17.0%) 5 (4.4%) 10 (7.6%) 
119 
(29.8%) 
86 (21.5%) 
Previous PCI 
139 
(23%) 
143 
(24%) 
172 (21.8%) 164 (21.1%) 90 (21.2%) 83 (20.5%) 31 (12.0%) 19 (12.9%) 3 (2.7%) 6 (4.5%) 51 (12.8%) 41 (10.2%) 
Previous CABG 36 (6%) 42 (7%) 69 (8.8%) 68 (8.8%) 39 (9.2%) 38 (9.4%) 10 (3.9%) 6 (4.1%) 5 (4.4%) 2 (5.3%) 28 (7%) 17 (4.2%) 
Clinical indication             
   Stable angina 
201 
(34%) 
215 
(36%) 
556 (70.5%) 546 (70.5%) 
147 
(34.7%) 
140 
(34.7%) 
89 (34.5%) 55 (37.4%) – – 256 (32%) 
   UAP/NSTEMI 
209 
(37%) 
208 
(35%) 
233 (29.5%) 229 (29.5%) 212 (50%) 
199 
(50.0%) 
95 (36.8%) 50 (34.0%) – 
113 (100%) 
– 
132 (100%) 
144 (18%) 
   STEMI 65 (11%) 62 (10%)   65 (15.3%) 62 (15.3%) 74 (28.7%) 42 (28.6%) 400 (50%) 
Multivessel CAD 
202 
(34%) 
183 
(31%) 
503 (63.7%) 494 (63.8%) 
285 
(67.2%) 
176 
(68.3%) 
131 (50.8%) 78 (53.1%) 18 (15.9%) 19 (14.4%) 
150 
(37.4%) 
158 
(39.5%) 
Treated coronary 
artery 
            
   LAD 
320 
(54%) 
313 
(52%) 
– – 
234 
(55.2%) 
196 
(48.5%) 
144 (55.8%) 82 (55.8%) 50 (44.2%) 50 (37.8%) 
243 
(60.7%) 
253 (63%) 
   LCX 
177 
(30%) 
159 
(27%) 
– – 
141 
(33.3%) 
155 
(38.4%) 
59 (22.9%) 41 (27.9%) 15 (13.2%) 16 (12.1%) 
127 
(31.7%) 
120 (30%) 
   RCA 
213 
(36%) 
227 
(38%) 
– – 
162 
(38.2%) 
161 
(39.9%) 
109 (42.3%) 58 (39.5%) 46 (40.7%) 64 (48.4%) 
153 
(38.1%) 
142 
(35.3%) 
   Left main 23 (4%) 8 (1%) – – 26 (6.1%) 27 (6.7%) 3 (1.2%) 3 (2.0%) 1 (0.01%) 1 (0.01%) 30 (7.6%) 33 (8.3%) 
CABG — coronary artery bypass surgery; CAD — coronary artery disease; LAD — left anterior descending artery; LCX — left circumflex artery; MI — myocardial infarction; NSTEMI — non-ST-
segment elevation myocardial infarction; PCI — percutaneous coronary intervention; RCA — right coronary artery; STEMI — ST-segment elevation myocardial infarction; UAP — unstable angina pectoris 
 






